Quick Answer
Dogwood Therapeutics, Inc. reported Operating Income of -$27.97 million for fiscal year 2025.
Dogwood Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$27.97M | -128.7% |
| 2024 | -$12.23M | -124.5% |
| 2023 | -$5.45M | +55.8% |
| 2022 | -$12.32M | +21.3% |
| 2021 | -$15.64M | -56.3% |
| 2020 | -$10.01M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$15.81M | -587.0% | -303.0% |
| June 30, 2025 | -$3.92M | -266.7% | +11.4% |
| March 31, 2025 | -$4.43M | -237.1% | -92.5% |
| September 30, 2024 | -$2.30M | -80.6% | -115.1% |
| June 30, 2024 | -$1.07M | +27.6% | +18.6% |
| March 31, 2024 | -$1.31M | +15.6% | -3.1% |
| September 30, 2023 | -$1.27M | +50.8% | +13.7% |
| June 30, 2023 | -$1.48M | +59.8% | +5.1% |
- Dogwood Therapeutics, Inc. showed a decrease of -128.7% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Dogwood Therapeutics, Inc.’s operating income has declined by 179.5% (from -$10.01 million to -$27.97 million).
- The most recent figure is from Dogwood Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: